For related articles and more information, please visit OCA’s Health Issues page and our Appetite For a Change page.

Why has Big Pharma failed to produce new antibiotics for deadly infections like MRSA (methicillin-resistant Staphylococcus aureus), VRE (vancomycin-resistant enterococci), C. Difficile and Acinetobacter baumannii even as they leap from hospital to community settings? Because there is no money in it.

Pharma executives “have shown less interest in medicines like antibiotics that actually cure disease than in those that only treat symptoms,” writes Melody Petersen, author of Our Daily Meds. “Most blockbusters are pills for conditions such as anxiety, high cholesterol or constipation that must be taken daily, often for months or years. They are designed for rich Americans who can afford to buy them.” Nor are medicines for tropical diseases like malaria, which kills a child every 30 seconds, a priority, notes Petersen. They also lack ka-ching.

Since direct-to-consumer drug advertising debuted in the late 1990s, the number of people on prescription drugs — especially prescription drugs for life — has ballooned. Between 2001 to 2007 the percentage of adults and children on one or more prescriptions for chronic conditions rose by more than 12 million, reports the Associated Press and 25 percent of US children now take a medication for a chronic condition. Seven percent of kids take two or more daily drugs. Who says advertising doesn’t work?